com: Stock Details.


Catalyst Pharmaceuticals's Net Income has grown In the last two years, rising from $31. .

424B4 1 g02464b4e424b4.

Company profile for Catalyst Pharmaceuticals, Inc.

At Catalyst, we are laser-focused on developing therapies for rare. Locations. Revenue.


) at RocketReach. Vitamin B 6-Pyridoxine. .

Catalyst Pharmaceuticals is a biotechnology business based in the US. Listen, Devise, Breakthrough.



Investor Contact Mary Coleman Catalyst Pharmaceuticals, Inc. Catalyst Pharmaceuticals's Net Income has grown In the last two years, rising from $31.

. .

Shares of Catalyst have returned 107.
The FIRDAPSE Pregnancy Registry: In conjunction with the FDA, Catalyst Pharmaceuticals has created a registry to collect information about the safety of FIRDAPSE use during pregnancy.

Sr Director, Corporate Development @ Impax Laboratories; Executive Director, Global Business Development @ ACTAVIS, INC.

We are focused on developing and commercializing innovative therapies for people with rare neurological diseases.

United States of America. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that it will release its. .

Catalyst Pharmaceuticals Inc. Phone (305) 529-2522: Website: catalystpharma. . . The trading price of Catalyst Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 76-0837053 (State of jurisdiction of.

355 Alhambra Circle, Suite 801 Coral Gables, FL 33134; Support: (305) 420-3200 [email protected].

CORAL GABLES, Fla. Catalyst Pharmaceuticals.

(CPRX) stock news and headlines to help you in your trading and investing decisions.

Get David Ailinger's email address (a*****@juno.



Catalyst Pharmaceuticals conducts research on and manufactures biopharmaceuticals for the use of treating neurological diseases.